Logo image of AMLX

AMYLYX PHARMACEUTICALS INC (AMLX) Stock Fundamental Analysis

NASDAQ:AMLX - Nasdaq - US03237H1014 - Common Stock - Currency: USD

3.3  -0.22 (-6.25%)

After market: 3.34 +0.04 (+1.21%)

Fundamental Rating

3

Taking everything into account, AMLX scores 3 out of 10 in our fundamental rating. AMLX was compared to 194 industry peers in the Pharmaceuticals industry. AMLX has a great financial health rating, but its profitability evaluates not so good. AMLX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AMLX had negative earnings in the past year.
AMLX had a negative operating cash flow in the past year.
AMLX had negative earnings in 4 of the past 5 years.
AMLX had negative operating cash flow in 4 of the past 5 years.
AMLX Yearly Net Income VS EBIT VS OCF VS FCFAMLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 -50M -100M -150M -200M

1.2 Ratios

AMLX's Return On Assets of -103.49% is on the low side compared to the rest of the industry. AMLX is outperformed by 78.38% of its industry peers.
AMLX has a worse Return On Equity (-132.24%) than 63.24% of its industry peers.
Industry RankSector Rank
ROA -103.49%
ROE -132.24%
ROIC N/A
ROA(3y)-41.47%
ROA(5y)-170.6%
ROE(3y)-48.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AMLX Yearly ROA, ROE, ROICAMLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 500 -500

1.3 Margins

AMLX has a better Gross Margin (78.88%) than 84.32% of its industry peers.
The Profit Margin and Operating Margin are not available for AMLX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AMLX Yearly Profit, Operating, Gross MarginsAMLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -10K -20K -30K

More info and screens

7

2. Health

2.1 Basic Checks

AMLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AMLX has been increased compared to 1 year ago.
There is no outstanding debt for AMLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AMLX Yearly Shares OutstandingAMLX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M
AMLX Yearly Total Debt VS Total AssetsAMLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

AMLX has an Altman-Z score of 0.05. This is a bad value and indicates that AMLX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.05, AMLX is in line with its industry, outperforming 53.51% of the companies in the same industry.
AMLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.05
ROIC/WACCN/A
WACC9.77%
AMLX Yearly LT Debt VS Equity VS FCFAMLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

A Current Ratio of 4.55 indicates that AMLX has no problem at all paying its short term obligations.
The Current ratio of AMLX (4.55) is better than 62.70% of its industry peers.
AMLX has a Quick Ratio of 4.55. This indicates that AMLX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.55, AMLX is in the better half of the industry, outperforming 63.78% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.55
Quick Ratio 4.55
AMLX Yearly Current Assets VS Current LiabilitesAMLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for AMLX have decreased strongly by -9150.00% in the last year.
Looking at the last year, AMLX shows a very negative growth in Revenue. The Revenue has decreased by -33.21% in the last year.
AMLX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 736.74% yearly.
EPS 1Y (TTM)-9150%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-456.67%
Revenue 1Y (TTM)-33.21%
Revenue growth 3Y736.74%
Revenue growth 5YN/A
Sales Q2Q%-99.59%

3.2 Future

The Earnings Per Share is expected to decrease by -26.04% on average over the next years. This is quite bad
AMLX is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -43.51% yearly.
EPS Next Y-731.31%
EPS Next 2Y-110.12%
EPS Next 3Y-62.89%
EPS Next 5Y-26.04%
Revenue Next Year-76.87%
Revenue Next 2Y-41.42%
Revenue Next 3Y-90.53%
Revenue Next 5Y-43.5%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AMLX Yearly Revenue VS EstimatesAMLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
AMLX Yearly EPS VS EstimatesAMLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AMLX. In the last year negative earnings were reported.
Also next year AMLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMLX Price Earnings VS Forward Price EarningsAMLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMLX Per share dataAMLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

AMLX's earnings are expected to decrease with -62.89% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-110.12%
EPS Next 3Y-62.89%

More info and screens

0

5. Dividend

5.1 Amount

AMLX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMYLYX PHARMACEUTICALS INC

NASDAQ:AMLX (2/21/2025, 8:01:05 PM)

After market: 3.34 +0.04 (+1.21%)

3.3

-0.22 (-6.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-20 2025-02-20/amc
Earnings (Next)05-07 2025-05-07/bmo
Inst Owners62.84%
Inst Owner Change-95.79%
Ins Owners8.26%
Ins Owner Change0.9%
Market Cap282.78M
Analysts80
Price Target8.16 (147.27%)
Short Float %3.63%
Short Ratio3.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-22.89%
Min EPS beat(2)-47.75%
Max EPS beat(2)1.96%
EPS beat(4)1
Avg EPS beat(4)-494.13%
Min EPS beat(4)-1860.78%
Max EPS beat(4)1.96%
EPS beat(8)4
Avg EPS beat(8)-209.32%
EPS beat(12)5
Avg EPS beat(12)-186.7%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.67%
EPS NQ rev (1m)3.7%
EPS NQ rev (3m)3.7%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.18%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.13%
Revenue NY rev (3m)0.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.44
P/FCF N/A
P/OCF N/A
P/B 1.44
P/tB 1.44
EV/EBITDA N/A
EPS(TTM)-1.85
EYN/A
EPS(NY)-1.69
Fwd EYN/A
FCF(TTM)-1.54
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS2.29
BVpS2.29
TBVpS2.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -103.49%
ROE -132.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.88%
FCFM N/A
ROA(3y)-41.47%
ROA(5y)-170.6%
ROE(3y)-48.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.78
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3521.21%
Cap/Sales 18.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.55
Quick Ratio 4.55
Altman-Z 0.05
F-Score3
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)443.46%
Cap/Depr(5y)N/A
Cap/Sales(3y)44.13%
Cap/Sales(5y)31.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9150%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-456.67%
EPS Next Y-731.31%
EPS Next 2Y-110.12%
EPS Next 3Y-62.89%
EPS Next 5Y-26.04%
Revenue 1Y (TTM)-33.21%
Revenue growth 3Y736.74%
Revenue growth 5YN/A
Sales Q2Q%-99.59%
Revenue Next Year-76.87%
Revenue Next 2Y-41.42%
Revenue Next 3Y-90.53%
Revenue Next 5Y-43.5%
EBIT growth 1Y-1446.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-703.05%
EBIT Next 3Y-86.33%
EBIT Next 5YN/A
FCF growth 1Y17.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.97%
OCF growth 3YN/A
OCF growth 5YN/A